It's been a banner year so far for Genfit S.A. (GNFT), a late-stage biopharmaceutical company developing drugs for rare and life-threatening liver diseases, whose stock price touched a two-year high of $6.13 yesterday.The company has 5 assets that focus on Acute-on-chronic liver failure and its complications, of which two are in the clinical stage and three are in preclinical development. Acute-on...
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.